Company news
Solvonis Therapeutics Plc (LSE:SVNS) news
Solvonis Therapeutics Plc news releases on 6ix. Latest, Mar 18, 2025: Update on AWKN-SDN-14 programme
Press releases — page 2
Update on AWKN-SDN-14 programme
March 18, 2025
Appointment of Non-Executive Director
March 11, 2025
Presentation at PharmaSynergyRx Event
February 25, 2025
Entry into an Arrangement Agreement with Awakn
February 24, 2025
Proactive Investors interview with Chairman
January 30, 2025
Update on Awakn Life Sciences’ R&D Progress
January 27, 2025
Investor Presentation
January 24, 2025
Proactive Investors interview with CEO
January 21, 2025
Interview with CEO
January 15, 2025
Change of Name to Solvonis Therapeutics plc
January 14, 2025
Result of General Meeting and change of name
January 6, 2025
Proactive Investors Interview with CEO and Chair
December 18, 2024
Proposed acquisition of Awakn Life Sciences Corp
December 16, 2024
Initial Results University of Nottingham
December 11, 2024
Notice of GM and proposed name change
December 3, 2024
Research Agreement
October 15, 2024
Research and development update
October 4, 2024
Non Regulatory-Interview with Dennis Purcell
September 26, 2024
Commercial Collaboration Progress Update
August 28, 2024
Directorate Change
August 12, 2024
Non Regulatory Appnt of Senior Scientific Advisor
July 30, 2024
Commercial Collaboration
July 23, 2024
Patent Filings
July 11, 2024
Admission & Director/PDMR Shareholding
July 10, 2024
Result of AGM
June 28, 2024
Business Update
June 7, 2024
Notice of AGM
June 4, 2024
Patent Application
May 31, 2024
Regulatory Application
May 28, 2024
Update on recent developments
May 9, 2024
Grant of Haemostatic Hydrogel Patent
May 7, 2024
Divestment of Graft Polymer d.o.o – Slo facility
May 3, 2024
Replacement of Chief Executive Officer
May 2, 2024
Annual Financial Report
April 30, 2024
Loan facility update
April 23, 2024
Chairman & Directorate Change & Financial Update
March 15, 2024
GM Statement
January 8, 2024
GM Notice 8th January 2024
December 27, 2023
Placing of New Ordinary Shares
December 22, 2023
Pivotal Agreement within European Consortium
October 9, 2023
Updated Investor Presentation
September 27, 2023
R&D Agreement with Slovenian Faculty
September 11, 2023
R&D and supply agreement with FORPET BALTIC
September 4, 2023
R&D Supply Agreement Signed
August 30, 2023
Graft Bio signs manufacturing services agreement
August 23, 2023
Distribution agreement with US Inter-Technologies
July 26, 2023
New R&D and Supply Agreement with Gabriel Chemie
July 6, 2023
Operational Update
July 5, 2023
AGM Notice
July 4, 2023
Director Share Purchase
May 16, 2023